E Fund Management Co., Ltd. Allogene Therapeutics, Inc. Transaction History
E Fund Management Co., Ltd.
- $1.8 Billion
- Q2 2024
A detailed history of E Fund Management Co., Ltd. transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 25,333 shares of ALLO stock, worth $73,719. This represents 0.0% of its overall portfolio holdings.
Number of Shares
25,333
Previous 37,130
31.77%
Holding current value
$73,719
Previous $165,000
64.24%
% of portfolio
0.0%
Previous 0.01%
Shares
10 transactions
Others Institutions Holding ALLO
# of Institutions
176Shares Held
132MCall Options Held
94.3KPut Options Held
112K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$54.5 Million1.08% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$47.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.2MShares$23.8 Million0.0% of portfolio
-
State Street Corp Boston, MA7.67MShares$22.3 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA6.9MShares$20.1 Million0.0% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $418M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...